SLRN - Earnings call transcript Q3 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to the Acelyrin, Inc.

Third Quarter 2024 Financial Results and Company Update Conference Call. This conference call is being recorded today, November 13, 2024. I would now like to turn the call over to Tyler Marciniak, Vice President of Investor Relations and Corporate Affairs. Tyler?

Tyler Marciniak

Victor. Thanks, and Conference joining Call. everyone, Third for you XXXX Quarter thank afternoon, us for Acelyrin's Good and and With Chief Officer. Labrucherie, Officer Executive today Officer; Business me are Gil our Mina Chief Chief Mpofu, our Shephard Kim, our Chief Medical Officer; Financial issued detailing third results release quarter earlier updates. important corporate news a financial We our and trials, And audience as may clinical remarks statements such future that those of begin to our contain ability call, progress our product like I'd results and today's we candidates. operating our before to the the related and remind financial our commercialize forward-looking our investments to We is and urge which factors to the available actual at website also XXXX, the with was the for of our results, Risk Factors performance with you on differ Form press certain our to XX-Q our identifies XX, along release, review which ended Acelyrin.com, that filed which September today's cause materially. and quarter could events today section SEC

are would available obligation to on statements the no as may circumstances Finally, information them Mina. to undertake today, I now to change. to November XXXX, call turn we update our based like XX, and over us

Mina Kim

and joining Tyler, for us today. Thanks, everyone, thanks,

in both uveitis. progress and TED. months pleased lonigutamab, strategy. our made of lonigutamab our development candidate, non-interior on ongoing as transformative The late-stage that first we our as to in announced are of treatment for our progress of IIb/III pipeline thyroid product August, and refocusing developing trial our lead upcoming for disease we're we a with focus the efforts were X milestones program anticipated we Izokibep Acelyrin, with our for In Phase Today, which noninfectious pipeline XXXX for our corporate we've the eye and strategic will reprioritization review as or well

delivered in known in a well tissues as XXX,XXX both optic lead proptosis progress Double of U.S. a is to bulging vision-threatening to delivered which as the close the more the like this of compression occur X lonigutamab, eye diplopia is and as clinical our the TED. of as people impacting only of I'd targeting a can shared progressive also treatment eyelids. positive nerve, which rapid in approved than the review anti-IGF-XR eye, the MOA, year, IGF-XR, weeks inflammation humanized TED proof-of-concept within action proptosis a potential inflammatory is for for monoclonal in to blindness. for there well TED patients, expansion as IgGX our the activity first subcutaneously disease the scores first antibody alone. the after can autoimmune chronic or and vision inability which we lonigutamab data subcutaneously the TED for dose. resulting behind demonstrating disease mechanism the in improvements on First, subsequent Earlier is

stays X agents. especially the II to both that above that lonigutamab mitigate with adaptive minimum XX of In XX continues optimal and maintaining other cement efficacy the on with that weeks hearing-related a in Cmax we're same Our weeks a therapeutic an dosing in the kind we now through agents Phase and evident for Phase We've anti-IGF-XR completed effort have and dose a and and window dose, X are which a safety trial selecting dose-finding follow-up. observed is effective registrational these focused with drive program. minimizes establish now of III with line to regimen narrow to dose multiple certain and of cohorts liabilities, level events cohorts dose

X expected fourth mg We tested mg, loading monthly XX that a previously are weekly Cohort reminder, loading As a included followed mgs QXW. mg dose. to shifted QXW we and announced was dosing with X cohort XXX either We adding this dosing a at XX or mg QXW. QXW to now our be to Cohort mgs Phase have started XX of That XX XX dose by no but cohort II cohort trial.

to dose. cohort used this the PK using confirm loading model primarily we've are We

We're Cohort that to cohort Cmax, steady-state we think that in not the We using we detailed benefit. with time a and think lines. may to will demonstrated this patient experience ensure as program used at the cohort III Hertel deliver help in X, first results the fully the Cohort full first is MRI assessments early time loading proptosis cohorts announce program. addition MRI example, Cohort rapid design For dose X this from measurements. enroll continuing of Phase execution as X cohort the Phase smooth X also faster III could we achievement to are be which assessments and where measure enrolled well and

with response we're our loading Given the ability this but of delivers trials one communities. cohort safety now met with lonigutamab being X to Phase And us manner. agents, the to have physician been which This really we better dose, AAO. far and with gives multiple believe last used FDA our patients, strategy, and communities We're timely Phase during the in response presented the with And III profile. third confirm a on first in at start right from the seen quarter that encouraged TED has congresses, profile, III our The confident need in options ability alignment our is the patient ASOPRs, response deliver treatment KOL presented from to patient and excitement the also TED including improved first by IGF-XR for risk-benefit dosing potentially a so for international enroll medical dosing cohorts. exploration efficacy for demonstrates patient data quarter, a program the this and were also XXXX. both ESOPRS the with confidence the completed even in our largely

Phase the meeting The request was III end of the We with goal approach a positive important secondary dose. TED. also and in on received program, the primary alignment recently completed Phase Phase proposed to feedback registrational meeting III II lonigutamab in size, achieve elements differentiated of of proposed with to and developing design, were and endpoints with We our pleased the including alignment FDA. to

also inactive on active XX dosing have upcoming our event approach early We patients. XX to both beyond to in TED and with our weeks details patients in and weeks to at We aligned the agency further out look sharing forward investor XXXX.

also world-class brings development. Phase uveitis III But important results perspectives we to trial in line Finally, Board to input, top announce provide as izokibep Patient December. a before together Scientific to IIb/III patient recently we prepare that for milestone and advocates established patient Advisory expertise clinical into and clinical and strategic Phase our we that lonigutamab of advance clinicians expect occurs, in

we and very development uveitis HS future a our with to stand-alone As data. internal path earlier one presents about the HS as different indication development and will we of opportunity. tied decision izokibep plans a make discontinue for and to development the for not The uveitis decision in PSA, a see after PSA

now top if the patient as Importantly, unmet population currently walk more izokibep detail. need. a you in treatments. orphan a program approved line about We it especially look we potential demonstrate entire along And the in program potential outcomes data, December. changes for that, data update on Shep through patient in indication with uveitis providing with uveitis, This compared improved the uveitis turn opportunity our uveitis to are over the to thinking materially very high the to with an I'll forward to

Shephard Mpofu

Uveitis complex varies pathophysiology Mina. that you, It characterized greatly. inflammation. is is Thank heterogeneous ocular is a disease by and the

cause insults uveitis cause a multifactorial, exact of can immune the remains ocular aberrant cytokine play imbalances role. Although damage and tissue key

to there are are developed retinal XX Loss that Unfortunately, risk uveitis XX management XX% and working is challenges is of to So at-risk and significant diagnosis macular blindness group the detachment, with age leads patients and in developing a surprising at to it demographically in this most key These not of of disease. ages in cases population in years. glaucoma often of countries. vision concern cataract, edema. X% is

high treatment As both and of in diagnosis unmet the is a above, noted uveitis. need there

patients better a thinking uveitis. role for uveitis potential targeting of kg per treatment systemic about mg corticosteroids corticosteroids, uveitis The treatments, In a only these per is interleukin-XXA term of treatment approximately secukinumab, demonstrated X an which as for in of response of for terms with that effects. was future patients, it a long monoclonal be for due rationale of options, consists cannot antidrug really previous associated In there kg and trials, response approved for adalimumab. is well-established than mg rate the maintained innovation patients interesting adalimumab XX to and on clinical half proof-of-concept as the uveitis. treatment is In the adalimumab. inhibition need with first-line scientific IV side medical and antibody IL-XXA treatment unmet is have biologic of there an Adalimumab half efficacy only lose approximately Thus, antibodies. XX showing and XX% dosing approved failed

X/XX shown that per and hand, other secukinumab. XX be can and molecular trials that milligrams X:X large the kg is in combined adimumab we was run the this placebo. approximately designed to we and trial more size were loss to blood of XX with to shown a preclinical In to delivered trial the the patients therapeutic to size, significantly to barrier every when we that in our enrollment to size to is potency due XXX signal a similar inhibit XXX izokibep on the drug than be with exposures of delivered subcutaneously, high from every time week subcutaneous, endpoint interleukin-XXA lost. relatively I izokibep potent The In is deliver of study, also of izokibep, versus can antibody. primary its other a monoclonal have secukinumab antibody IIb/III shown small efficacy. milligram active potency IV randomized May, have to with penetrate retinal is when failure. small izokibep a VISUAL designed drug study, Further, treatment dose-dependent protein size, treatment that week Phase the hypothesized However, completed uveitis moving reduced It monoclonal the contributed mg of exposure of higher have using manner. similar smaller IV secukinumab subcutaneously

as done In failure weeks. a addition, of VVISUAL VISUAL line weeks. endpoint I In results, XX with I, at the be demonstrated treatment top our was XX% landmark XX a will placebo adimumab out over read in benefit at rates

readout, be data for our is As to for guess outcome additional positive, will the upcoming we to required registration. superior clinical Phase XXX Phase IIb/III approximately we our of will of that adalimumab. forward to Should be is that be a trial patients one that look best XXX III looking data

orphan has uveitis the would top of we pricing, potential associated any the certainly need However, look look given from helpful, an the disease, hope and with been to on confer authorities high of drug health accelerated potential overview acknowledgment our you approval. pathway the like line sharing uveitis to December. this orphan the FDA's with to unmet and with as I results we that forward trial for

the let results. call Now our over to turn a Gil financial me quarter review for third of

Gilbert Labrucherie

the We conference HS remain decrease for the ended Thank XXXX. $XXX.X to financial in activity schedule a compared Great. Today, in ended in XXXX. reduced reported trials and expenses on we development of development result with substantially as financial and and third the a you, out The in Research our izokibep primarily XX, pipeline to August position same execute Phase plan results were for quarter for $XX.X continue period PSA Shep. III prioritization our the with call. the quarter we million strong We complete. million quarter September million the laid $XX.X clinical for in are as cash. was very

administrative compared same $XX.X quarter, period XXXX. third were million a and The expenses lower the to $XX.X the for result compensation expense. For of decreases million were in stock-based primarily general

commitments reported recently resolved on very X, restructuring. quarter fully as in identified part izokibep pleased are Form last we X-K manufacturing that to amended we our for November As we of have filed an outstanding

accompanying voucher development a be including manufacturing $XX.X already significant net of towards Our Phase XXXX. services, in together the team successful of can III million, voucher. payment only This manufacturer supply, consists to working on expense a was million where million. this of lonigutamab with credit future manufacturing liability advance front are to expense This program contractual $XX.X actively the directly QX to transforming $X.X in credit any an applied a we net into

outflows. the We XXXX directly would have and XXXX to offset expect first credit this otherwise quarter to cash in what of been utilize

to year-end with of $XXX $XXX pleased August, million. have this, this cash very are our all XXXX we We announced of million position in And guided associated with this substantially expenses the with we August a outcome. restructuring year. incurred to of In

QX With licensing This acquire the to to cash guidance guidance now to $XX payment in the all updating manufacturing commitments license resolved, year-end we million. option year-end rights partner. anticipated million million includes are lonigutamab our cash $XXX global $XXX from to

position last include lonigutamab, As least manufacturing including includes runway quarter, operational any program for activities uveitis. entire stated the we mid-XXXX. our This at to but to runway gives new both BLA izokibep, through development current including not Phase a and potential in development does cash projection investments us filing, III

not are this at we million also XXXX, pending development voucher of our engage our further could in the part While provide put we changing runway as to include quarter. our place guidance upcoming most gives to expansion uveitis future review the flexibility do data. in flexibility. of us wanted credit for corporate which cash $XX.X biotechs more ATM manufacturing selective the even I time, an capital Like pipeline are to for one to facility eligible today, administrative who infrastructure so, in note make of

Our efficiency I now will capital high-quality focus turn closing heading will remain for on into to and disciplined Mina remarks. XXXX call allocation, back execution. the

Mina Kim

thanks, thank work. our both in lonigutamab Shep. TED of and proud team for I hard and make to continuing we're Gil, uveitis. in entire to the And their We're want with progress izokibep continued Thanks,

We these year disciplined We to to to and have transformative support a months, we who to questions. and few continue decisions share and new goals number just to XXXX. appreciate financial which and in maintain our potentially position next make of strong the from as bring important that, treatments remainder need for with a achieve to And of patients and we'll updates ready clinical them. to take continued corporate we're work the capital-conscious your this into the

Operator

[Operator Instructions].

will Our from of question line TD come Cowen. first from Tyler the Van Buren

Tyler Van Buren

couple programs particular. and decreased you progress in on operating I for cost to controls the clinical a expenses of and Good see the lonigutamab. improved have

II you just can III if And the trying you from will see during understand XXX dose to end the So in dose is us data it Phase dose Cohort a Cohort partial range and fair XXmg the better X data. FDA just, X I X saw second what first they in did the somewhere Cohort of from the I'm to didn't Or TED propose data understand X? could help data for likely trial cohorts? guess the it they to Was how meeting? being say mg the Phase a pivotal is that question include tested X? see

Mina Kim

Yes.

So Tyler, thanks for the questions.

in to sure So FDA, role of that I kind X that in the we what's answering, going cohort second the that and XXX, then I'm meeting? end that was One think there. they the II are of want I questions the was to of right? had purpose And the the what XX show just What's or Phase what X, Is program? part make was play, did of you the right, fair? what

Tyler Van Buren

Yes.

Mina Kim

Yes. Okay.

monthly, a in where been meeting, right? showed data Phase an right, this with of end Phase mg first that way. that's sorry, As of we are includes the of is over regimens FDA mg, I we've had, pretty time. that along testing And what from II with and with what mean II end right? Cohort weekly X XXmg meeting know, to that we to is trial doses XXX kind you on open-label X the right? the really with maybe those typical maturing So with And them data cohorts that maturing XXX -- we had

with right, do our well a band, very have modeling. narrow And to in behaved, has ranging. So data, that's been where the a that's molecule consistent frankly, dose pretty right, very which we

that important right, so a is and input obviously is here. pretty And helpful,

of we've And with sort we the thinking so had, how aligned dosing of II meeting, we to data that the taken and Phase that the end totality them it. took an approach we're to of we and about on and

for just dose, is the X, in patient time said that script, informed faster. to loading about in try responses, period us to Like Cohort that's there totality benefit that again, XX decision. therapeutic right? thinking shorter to the the And to as we're right, and really get to And get that of faster provide to of so window -- a I XXX opportunity narrow an the in just to a

thinking X And so Cohort that's dose. really how that about we're

And does as so it role, have fairly right, a dosing. about narrow we think

Operator

Our comes question Akash next the of from Jefferies. line Tewari from

Unknown Analyst

in [indiscernible] is This Akash. for

exposure a enough if XX efficacy per like XX%, driven XXX-milligram kilogram UA Molar And izokibep kilogram, Just in bring one gives XX%. to that let's you let's be benefit? expecting efficacy to the comes, similar secukinumab milligram What significant see to you are a lower Cmax say, IV? Will question. say, that confidence than slightly XX-milligram clinical is secukinumab

Mina Kim

the Thanks for and to I right the answering question. want the we're hearing just make sure question. question

curious think secukinumab sort how and about, you're we about do the of I to other potency think I programs? relative the XXX guess, equivalency to

Unknown Analyst

Yes.

Mina Kim

Yes. Okay.

And could of sort what program? benefit, the see that right, clinical potential that we in in of terms mean does uveitis

Unknown Analyst

Yes.

Mina Kim

I'm to Yes? that actually going Okay. one. Shep to ask take

Shephard Mpofu

Yes. No, question. the thanks for

done secukinumab. arthritis that work have of as at And the of our significant if for HS, amount the we its equally presentations some potency. started and of clear we is based program we exposure on you very commensurate understanding a a derived on So psoriatic izokibep to potent look

we the have presence XX kg of us exposure within have our all secukinumab very some have the we vitreous izokibep uveitis, done with humor. are we subcu In that enabled fortunate of find that week. to every the X primate various to subcu mg studied So across and per sets data indications every weeks modeling IV our XXX-milligram in of equates autoimmune studies

possible XXx So than we secukinumab. know it's this smaller because is

penetrate able the blood it's to retinal barrier. therefore, So

therapeutic uveitis, And outcomes much you eye. expect set. question whether impact the improved the see we to in something of see asked into data terms hope in in terms gets the same a it a of We to potential So of abrogates also the present uveitis in we permeate that given antibody there. notion big to inflammation secukinumab do locally, abrogation are dual peripherally like because the mainly and opportunity systemically. and that monoclonal systemically eye the we have And

So see what something we demonstrated. better to than was hope

Operator

the Piper will Rahimi of Sandler. Yasmeen question next from come Our from line

Unknown Analyst

on [indiscernible] This is for Yas.

pivotal line case capital to III would uveitis, study Given how secondly, a what soon following Phase be base off top the for And you able study would December? commitment like? a look in the data in kick

Gilbert Labrucherie

for first -- piece take is question. This that the of Thanks the certainly the Gil. Yes. take I'll question.

So prepared hand mid-XXXX, we as uveitis our to I take runway to study, around we estimates the we given mentioned in with until out in uveitis do if decide we flexibility specific forward. develop the that's if further my have our us. runway we data for have significant to that any remarks, right do won't so probably within decision haven't But

that really forward have So about we and we with we options take good feel resources the the on hand. to are existing where it

Mina Kim

said, think the I'll one. as case, that. Yes. molecule and about that certainly going we're to warrants we we go Shep to And timing And acceleration FDA guidance, that in with ready need data patients, trial something kind like know that, XXX, is right, the a talk but specific maybe of XXX program our if potential right, to path base another would right, lines. the -- around take a I think guidance obviously, it's give But I any time we're don't really well.

at data, So we right out path figure the makes and on you sense to time. a right, then timing I think think update guys it what the take right look is the forward, at us we'll for

Operator

Fargo. from from come will line Wells of Archila question Derek the next Our

Unknown Analyst

uveitis. just market into in you thinking clinical the remind the entry are in how for the This Humira there And is Can currently about this Adam a population? on what Maybe patient meaningful given on opportunity you benefit us izokibep Derek. of market? constitutes one biosimilars

Mina Kim

Maybe I'll just Yes. start.

then benefit, a not are unmet thinking steroids patients in think, We adalimumab. do do right, And about, there about fail. we as uveitis, need, you're high is there's and Many if adalimumab clinical thinking perfect Shep noted, right, it's answer. is

primary are to we certainly reference there. is So it data, look adalimumab said, think for about offer improvement going there as at That differentiated? going as be that Is for the to the patients it profile us we to superior said, just to as And point room is going are a benefit? Shep bar. will compared clinical look adalimumab. a increased for we And so

Shephard Mpofu

a maybe is the to really add And this need. significant Mina not And said, population. just just on an there's There's now. here much front, market as Yes. unmet very right

within this izokibep benefit. about framework, to the think with market potential associated have a benefit we as we significant patient economics when with and that pricing orphan So see

Unknown Analyst

XX remains on that? And maybe just where one then disclosed III And this to Phase on to III regimen previously, Phase you it. you dose the confirm for go-forward you've lonigutamab's that I Got going be proposed any was dose the are is dosage. proposed Can the color that be believe in if -- milligrams. case?

Mina Kim

Yes.

we announced new that's not really in said dose test XXX have potential have is mg again, so regimens are we've loading dosed range cohort to the the that What we have right? and that a we And a tested And to and weekly XXX is that XX monthly. X mg, in pivotal dose, right? to

be provide announce pivotal details the on we'll in we that we that when announced III data will not yet program. it the do and the dose, of envelope, have and kind but Phase So

Operator

Wainwright. from comes from line the H.C. of Bodnar question Next Emily

Emily Bodnar

you instead of for guess mentioned looking the I weeks for Phase XX. XX at III, loni, you're

you'd to So are then for hope of you first quarter, frame? XX-week see of you just Phase what maybe III that And chronic the can just and clarify and planning durability talk initiate active TED? III kind about the you're beyond studies response how in Phase for thinking to about time to

Mina Kim

Yes.

start. And so maybe I'll

same improved effective to come that to safety show with FDA be work time. right? the alignment both XX patients, have doing I weeks. in can to that's we've think we on the dose at -- could a dosing right, differentiator to It's for think, but that, been do an testament, the we these that ability And us, real with out are agents we profile the potentially So a anti-IGF-XR

us the to do gives inactive And weeks and so think XX in we at active dosing out to the populations. ability look both that TED

the And right? trial that of is But Phase are so program that right, design. time those we'll development in about the sort complete parameters sort program. to provide picture III of we're the what think that about how said, lines, I and -- Like 'XX, a development thinking of I using think we're early that's

Shephard Mpofu

not we therapy, or Yes. Maybe therapies FDA we address therapies evidence are what dose to fold and approved high a exposures very clear is patients, it's current with are XXX with thyroid do that given eye in including able good the dose recurrence these time. in potential the relapse considerations be of post just arrive rationale add, over know also at real-world patients enough exposures mentioned, multiple the a lower keeping fully have on to safe a the address and very resolution, in than exposure autoimmune not XX current ranges really dysregulated if believe rate saw chronic where which disease a milligram, disease, disease of in immune And pathway unmet need. might Mina treatment. way to fixed safety in a modification disease having we of as to currently a There's

Emily Bodnar

the expected quarter? on first Phase active the III and And Okay. both in just are TED

Mina Kim

'XX. right? we'll in the And sort provided III -- design we details in level of about testing -- provide both haven't But early populations, we expect be to we're said, of going program the we detail. Like in Phase to that

Operator

Stanley. comes Our the line Vikram from from next of Morgan Purohit question

Vikram Purohit

So we had X.

next of And clinically as lonigutamab, then be hearing I open missed severity? impairment asked the and we previously would on partner PSA, consider data finding on this the apologies the you to mentioned versus if a a Tepezza terms that know well, and First, events of what and and in HS cut for would meaningful pivotal it. you then data benefit there. their secondly, But was in izokibep number you eventual

this So that if I be actioned like could BD any the see near there's And you midterm? if to feel wanted in interesting something to discussions. been is just

Mina Kim

over I'll Thanks Okay. question. BD hit the let's turn then and start to with and for Maybe it the can we Gil hearing. question,

Gilbert Labrucherie

program the the Yes, on here very up on to in for the going data front, BD December. shortly hand we're Vikram, have on uveitis izokibep, in coming

that included new at program. more we any talked we not the guidance can assumptions in that around investments earlier, izokibep. my in fulsome runway on we think or a you provide would about update time, I partnering just I remind have that

Shephard Mpofu

on And think alluded that's we associated a also I have potential really Mina overexposure impairment to Yes. hearing, mitigates the the this dose, been how hearing calibrating pathway. which on with

So asked at investor approaching will we how be of around able expecting, we what percentages are the Research share you our with as question -- are at you in our to Day hearing. early 'XX, we

objective do are hearing or sharecase patients Phase patients are And this with you therefore, that be approaching sensor not hearing more are aware, all neuro III you subpopulations. are we'll in and how able impact expecting whether changes be studies and baseline different might we impairment As currently more objectively assessments. assessing subjective we audiogram at just to having to quantify really what

have issues nature. pertaining of to various Let's forget XX% disease patients eye to also of impairment hearing thyroid that with not XX%

will on outcomes we to based those all have So explore important considerations.

'XX. to in more So come early

Operator

Citi. will question from next come Semenkow the of line Our Samantha from

Samantha Semenkow

really I'm to please. I mind you a of to does follow-up, for on, Humira, data if Humira? just it than And that way interesting for take line the better Is have following sort Is with the in bar a about the on in it prior make comes your success think question. forward? less it uveitis right

Mina Kim

Yes.

Let me start.

I right? whole the you data look think look, I is, and package. at story obviously, is it mean, always tells complicated a

at and what when have data something did patients -- that with is benefit, data we think we'll way clinical HS in really that And we to right? the of So that the is totality same this potential we'll the of the sort PSA, look need. about

But about said, that. profile for like I is is will in I'd general, would, so I think that look right? And that adalimumab we bar, a do think the say, better. so we And

Samantha Semenkow

allowing you're to worse. experienced about biologics and impact you are I'm just biologically potentially that patients do they've those the that and previously at very That's could then indications helpful. data other the approved how believe, of Humira just are study. the are when it. given Got study VISUALX trying that other experienced, thinking biologic And into how I because biologic about believe a think patients I naive, patients that seen time. there meaning And design, no study, lot look obviously, the at

trying how study that through your dynamic and just impact might So think results. to that

Mina Kim

For sure.

then and I'll let start, So me it Shef. turn over to

not adalimumab case, it was trial is right? different, because and different now, So we that approved. the patient is you're and are the adalimumab right, correct, So now population a

And so in trial. of do include those our we patients some are

And me then stop further there, I for any let over comments. to can it so and Shep turn

Shephard Mpofu

it's to for thank And have are an naive our the mature, patients. have versus at an question, in drug to we and and we that. be how randomization, of doing protocol numbers equal ascertain subpopulation, important we that we on obviously, these so No, stratify you point, for Yes. able placebo to patients that understanding your

small HS, overall where expect TNF would in patients PSA have you a fraction have these in blocker we this like population. is trials, usually, the a failing you As of or previously seen

in ISO patients total able what understanding the will take of as population, would a we of be those well impact patients have consideration of So for been failed in population a the have study. on the that an also naive result sure, and have adalimumab including and data to

come. more So to

Operator

Tyler turn call. to today's And over I'll with to now conclude Ford no more questions, it

Tyler Marciniak

and for you, joining Victor, today. Thank everyone, our you, thank call

line a in the our with the early the in and we press event continued by in IIb/III the forward for our you with in year sharing well as As as will Thank hosting one-on-one we today's you meetings many results Acelyrin. for to release, and upcoming interest investor izokibep lonigutamab your at fireside end Phase of in Conference with uveitis top in of conclude XXXX. participating look that, chat you London call. Jefferies noted And

Operator

This today's your conference. Thank participation you conclude does for in program. the

a disconnect. day. now Everyone, You may great have

Acelyrin (SLRN) 13 Nov 242024 Q3 Earnings call transcript